对于烧伤患者的牛津:从2005年到2025年随机对照试验的系统审查和更新的元分析
Jiaqi Lou1, Ziyi Xiang2, Xiaoyu Zhu3
1Burn Department, Ningbo No. 2 Hospital, No. 41 Northwest Street, Haishu District, Ningbo, 315010, Zhejiang Province, China.
World journal of emergency surgery : WJES
|September 30, 2025
概括
通过减少手术和住院治疗,牛德罗隆有助于燃烧恢复,同时改善肌肉质量和体重增加. 然而,它不会降低死亡率或感染率,并且在成年人中存在肝脏问题的风险.
科学领域:
- 在严重烧伤管理中使用类固醇治疗.
- 随机对照试验对烧伤患者的结果的元分析.
背景情况:
- 严重的烧伤会导致超能代谢,蛋白质代谢,并增加感染风险.
- 烧伤患者经常经历雄激素枯竭,恶化代谢障碍.
- 合成类固醇类固醇 (oxandrolone) 可能会抵消这些影响.
研究的目的:
- 为了评估oxandrolone在烧伤患者的疗效和安全性.
- 将最近的研究,儿科患者群体,长期结果和组合疗法纳入分析.
主要方法:
- 14个RCT (2005-2025) 的系统审查和元分析,涉及2822名烧伤患者.
- 搜索了 9 个数据库,比较牛士罗龙与安慰剂/标准护理的试验.
- 评估结果包括瘦身量,副作用,感染,死亡率,手术程序和停留时间.
主要成果:
- 牛类激素显著减少了手术程序 (SMD = -1.25) 和停留时间 (LOS/TBSA SMD = -1.07).
- 观察到增强的 anabolic 恢复与增加的体重增加 (SMD = 0.58) 和瘦肉质量 (SMD = 1.30).
- 没有发现死亡率 (RR = 1.04) 或感染率 (RR = 0.83) 的降低;成年人显示肝功能障碍增加 (19%与5%相比).
结论:
- 在临床上,oxandrolone对于减少烧伤患者的手术负担和住院治疗有用,促进了合成代谢的恢复.
- 高异质性需要谨慎解释;没有观察到死亡率或感染益处.
- 成人肝毒性风险较高,需要在代谢康复的同时进行风险分层的实施.
相关概念视频
01:22Burn Injuries
Burn injuries occur when the skin and underlying tissues are damaged due to exposure to heat, electricity, chemicals, radiation, or friction. They can vary in severity, from minor superficial burns to severe deep burns that can be life-threatening.
The damage results in the death of skin cells, which can lead to a massive loss of fluid. Dehydration, electrolyte imbalance, and renal and circulatory failure follow, which can be fatal. Burn patients are treated with intravenous fluids to offset...
The damage results in the death of skin cells, which can lead to a massive loss of fluid. Dehydration, electrolyte imbalance, and renal and circulatory failure follow, which can be fatal. Burn patients are treated with intravenous fluids to offset...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...